Refractory de novo myeloid sarcoma: a case report and therapeutic strategy based on bone marrow minimal residual disease

Inoue, Daichi; Nagai, Yuya; Kimura, Takaharu; Shimoji, Sonoko; Mori, Minako; Togami, Katsuhiro; Tabata, Sumie; Kurata, Michio; Matsushita, Akiko; Ito, Kiminari; Hashimoto, Hisako; Maruoka, Hayato; Yamashita, Eiko; Nagai, Kenichi; Imai, Yukihiro; Shirane, Hirofumi; Takahashi, Takayuki

doi:10.1007/s12185-009-0349-7

Cited by 7 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median time from the onset of initial symptoms to the development of AML is 5-12 months (7,21). In addition, AML-specific gene fusion has been detected in the bone marrow of patients with isolated MS, suggesting that even in patients with isolated MS, involvement of the bone marrow may have occurred earlier in the clinical course (22).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Acute Myeloid Leukemia Concurrent with Spinal Epidural Extramedullary Myeloid Sarcoma Accompanied by a High CD25 Expression and the <i>FLT3-ITD</i> Mutation

et al. 2014

View full text Add to dashboard Cite

Myeloid sarcoma (MS) is an extramedullary myeloid tumor that sometimes presents with antedating systemic leukemia, leading physicians to the misdiagnosis of lymphoma. CD25 is expressed in 13% of patients with acute myeloid leukemia (AML), and its expression is associated with FLT3-ITD mutations, an elevated serum soluble interleukin 2 receptor (sIL-2R) level and a lower survival rate. However, there are no reports concerning the relationship between MS and the CD25 expression. We herein report a case of AML accompanied by thoracic epidural MS with a high CD25 expression, the FLT3-ITD mutation and an extremely elevated serum sIL-2R level in a 59-year-old man who presented with paraplegia.

show abstract

Section: Discussionmentioning

confidence: 99%

“…MS usually occurs concomitantly with or after the diagnosis of AML (3)(4)(5). It may also present antedating the onset of systemic bone marrow leukemia (6,7), and many such cases are misdiagnosed as lymphoma (8). MS can occur in any organ, with common sites including the bones, lymph nodes, soft tissue and skin (9,10).…”

Section: Introductionmentioning

confidence: 99%

Acute Myeloid Leukemia Concurrent with Spinal Epidural Extramedullary Myeloid Sarcoma Accompanied by a High CD25 Expression and the <i>FLT3-ITD</i> Mutation

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, de novo GS is characterized by leukemic tumor formation without bone marrow involvement [2]. …”

Section: Discussionmentioning

confidence: 99%

“…In cases treated with radiotherapy alone or who received inadequate chemotherapy, AML could develop within 7 to 12 months, and the prognosis is very poor [2]. Thus, GS patients should be treated as in AML even in the absence of bone marrow involvement.…”

Section: Immunophenotyping Study Of Biopsy Materials Is Very Importantmentioning

confidence: 99%

See 1 more Smart Citation

Extramedullary Orbital Granulocytic Sarcoma Without Bone Marrow Involvement: A Report of Two Cases

Işık

Tavil

Tunç

et al. 2010

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

The authors present herein 2 extramedullary orbital granulocytic sarcoma (GS) cases without bone marrow involvement in view of their rarity and also to reevaluate the treatment approach in this disease. Seven days of high-dose methyl prednisolone (HDMP) treatment (3 days 30 mg/kg/day and 4 days 20 mg/kg/day) was administered initially, and subsequently Acute Myeloid Leukaemia-Berlin Frankfurt Münster (AML-BFM) 2004 treatment protocol was continued for 2 cases. Eye findings of the cases resolved considerably with HDMP treatment. They have still been under systemic chemotherapy without any complication for 1 year. Thus, early diagnosis and AML-targeted intensive chemotherapy improve the prognosis of GS even if there is no bone marrow involvement.

show abstract

Long-Term Remission following Autologous Hematopoietic Cell Transplantation in a Patient with Multiple Nonleukemic Myeloid Sarcoma and a Review of the Literature

Liang

Gao²,

Wu³

et al. 2017

Acta Haematol

View full text Add to dashboard Cite

Multiple nonleukemic myeloid sarcoma (MS) is a rare form of MS that is developed in multiple anatomic sites other than bone marrow at diagnosis, without a preceding myeloid neoplasm. The prevalence, prognosis, and optimal management of multiple nonleukemic MS have not been addressed. The role of allogenic or autologous hematopoietic cell transplantation (HCT) for nonleukemic MS is also less well defined. We present a case of MS characterized by systemic lymphadenopathies and multiple effusions, which presumably had a very poor prognosis. The patient was treated with acute myeloid leukemia-type induction chemotherapy and autologous peripheral blood stem cell transplantation, and, unexpectedly, she has remained disease free for more than 6 years. We also reviewed the literature on this rare disease, and found that multiple nonleukemic MS was associated with younger age and a worse prognosis when compared with the overall nonleukemic MS population. We suggest that autologous HCT represents a valid option for young patients with chemosensitive disease and should be performed at the status of minimal residual disease-negative complete remission.

show abstract

Refractory de novo myeloid sarcoma: a case report and therapeutic strategy based on bone marrow minimal residual disease

Cited by 7 publications

References 15 publications

Acute Myeloid Leukemia Concurrent with Spinal Epidural Extramedullary Myeloid Sarcoma Accompanied by a High CD25 Expression and the <i>FLT3-ITD</i> Mutation

Acute Myeloid Leukemia Concurrent with Spinal Epidural Extramedullary Myeloid Sarcoma Accompanied by a High CD25 Expression and the <i>FLT3-ITD</i> Mutation

Extramedullary Orbital Granulocytic Sarcoma Without Bone Marrow Involvement: A Report of Two Cases

Long-Term Remission following Autologous Hematopoietic Cell Transplantation in a Patient with Multiple Nonleukemic Myeloid Sarcoma and a Review of the Literature

Contact Info

Product

Resources

About